• Enanta Pharmaceuticals posted fiscal second-quarter revenue of USD 17.2 million, up 15.01% year over year, as net loss narrowed to USD 13.1 million, or USD 0.45 per share.
• Research and development expense fell to USD 19.4 million from USD 28.1 million, while general and administrative costs declined to USD 9.6 million from USD 11.4 million.
• Cash, cash equivalents, short-term and long-term marketable securities totaled USD 227 million at March 31, 2026; Enanta expects existing liquidity and retained royalties to fund operations into fiscal 2029.
• Phase 1 dosing began for EDP-978 in chronic urticaria, with topline data expected in fourth-quarter 2026; IND filing for STAT6 inhibitor EPS-3903 targeted in second-half 2026.
• Enabling work continued for a pivotal zelicapavir RSV study, with an update on design and development path expected in second-quarter 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260511989798) on May 11, 2026, and is solely responsible for the information contained therein.